Last reviewed · How we verify
NCT06748105: DAPACOID
Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia
Phase 2 trial testing Dapagliflozin (DAPA) in Dapagliflozin (Forxiga) in 38 participants. Participants enrolled and being followed up; not accepting new ones.
1 December 2025
Quick facts
| Lead sponsor | Lauro Fabián Amador Medina |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 38 |
| Start date | 1 December 2024 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Dapagliflozin (DAPA) — full drug profile →
Conditions studied
- Dapagliflozin (Forxiga) — all drugs for Dapagliflozin (Forxiga) →
- Hyperglycaemia — all drugs for Hyperglycaemia →
- Glucocorticoid — all drugs for Glucocorticoid →
Sponsor
Lauro Fabián Amador Medina
Who can join
18 and older, any sex, with Dapagliflozin (Forxiga) or Hyperglycaemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to investigate whether dapagliflozin can help prevent glucocorticoid-induced hyperglycemia (GIH) in hospitalized patients requiring high-dose glucocorticoids (GCs). This trial will also assess the safety of dapagliflozin when used alongside GCs. The main questions the trial aims to answer are: Does dapagliflozin reduce the incidence of GIH in patients receiving high-dose GCs? What side effects or adverse events occur in patients taking dapagliflozin alongside high-dose GCs? Researchers will compare dapagliflozin to standard glucose monitoring (SGM) to determine if dapagliflozin is effective in preventing GIH in patients receiving high doses of GCs. Participants will: Take dapagliflozin (10 mg/day) or undergo standard glucose monitoring during their hospital stay. Visit the hospital for regular check-ups and glucose testing during their treatment. Record their glucose levels multiple times a day and report any adverse events they experience.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06748105
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dapagliflozin (DAPA)
Trials testing the same drug.
- NCT06907251 — Dapagliflozin for Long COVID Syndrome · Phase 3 · not yet recruiting
- NCT06954090 — Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study · Phase 4 · enrolling by invitation
- NCT06922656 — Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Preven · Phase 4 · not yet recruiting
- NCT07120828 — The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity · Phase 4 · completed
- NCT07082114 — A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus · Phase 3 · recruiting
Other recruiting trials for Dapagliflozin (Forxiga)
Currently open trials in the same condition.
- NCT06668389 — Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06748105 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lauro Fabián Amador Medina
- Last refreshed: 27 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06748105.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing